Compare GoPro Inc (GPRO) vs TG Therapeutics Inc (TGTX) Price & Performance

GoPro (GPRO) trades at $1.19, down 2.46% on the day, as the stock consolidates following a volatile surge driven by merger news and influencer investment. The company shows concerning fundamentals with negative net income margins (-28.52%) and declining revenue trends, though valuation ratios appear attractive with P/E of 4.56 and P/S of 0.34. Recent developments include a planned $285 million merger with Starman Optical and significant stake acquisition by YouTube creator Markiplier, creating both opportunity and uncertainty.

The outlook remains highly speculative with the merger offering potential upside but facing shareholder litigation over valuation concerns. Investment opportunity exists if the Starman merger unlocks new AI/data center markets, but risks include persistent cash burn, competitive pressures from smartphones, and questions about the fairness of the $1.14 per share buyout price that could limit shareholder returns.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.